Inside the tactical tug of war over the controversial Alzheimer’s drug

February 17, 2022

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled—and hinted at a lawsuit—over the decision to pay only for patients taking the drug in a clinical trial.

Medicines360's long and winding, $82 million road to create and distribute $50 birth control
Drugs and medical devices rarely come from the nonprofit world. There are more than 2,600 for-profit pharmaceutical companies in the United States, but only three nonprofits have products on the American market.
LDL not the be all, end all in heart disease, heart attacks and stroke
Despite advances in treatment for high cholesterol, heart disease remains the leading cause of death in the U.S. Scientists at the Medical College of Wisconsin (MCW) are investigating the role of a form of cholesterol called very-low-density lipoprotein—and their findings may lead to new treatment options in the future.
Software analyzes calcium 'sparks' that can contribute to arrhythmia
A team of UC Davis and University of Oxford researchers have developed an innovative tool: SparkMaster 2. The open-source software allows scientists to analyze normal and abnormal calcium signals in cells automatically.
Precarious employment conditions can increase risk of early death
People without a secure job contract can reduce their risk of premature death by 20 percent if they gain permanent employment, a study from Karolinska Institutet published in the Journal of Epidemiology and Community Health reports. According to the researchers, the results indicate that job security on the Swedish labor market needs to improve.
Network-based approaches open a new avenue to classify and treat rare diseases
Network-based approaches often unveil what remains concealed—this holds true in medical research as well. For several years, CeMM Adjunct Principal Investigators Kaan Boztug, Director of St. Anna Children's Cancer Research Institute, and Jörg Menche, a professor at the University of Vienna and Max Perutz Labs have been working to gain a better systemic and molecular understanding of rare diseases, congenital immune disorders, and congenital inflammatory disorders by using network-based methods.

Inside the tactical tug of war over the controversial Alzheimer’s drug

Recent Posts

JUST IN